CN104902927A - 用于治疗用途的抗-bag3抗体 - Google Patents

用于治疗用途的抗-bag3抗体 Download PDF

Info

Publication number
CN104902927A
CN104902927A CN201480003897.1A CN201480003897A CN104902927A CN 104902927 A CN104902927 A CN 104902927A CN 201480003897 A CN201480003897 A CN 201480003897A CN 104902927 A CN104902927 A CN 104902927A
Authority
CN
China
Prior art keywords
antibody
bag3
use according
monoclonal
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480003897.1A
Other languages
English (en)
Chinese (zh)
Inventor
玛丽亚·卡特里纳·图尔科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phibrosis LLC
Original Assignee
Biouniversa SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa SRL filed Critical Biouniversa SRL
Publication of CN104902927A publication Critical patent/CN104902927A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Multiple-Way Valves (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480003897.1A 2013-03-18 2014-03-04 用于治疗用途的抗-bag3抗体 Pending CN104902927A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2013A000403 2013-03-18
IT000403A ITMI20130403A1 (it) 2013-03-18 2013-03-18 Anticorpi anti-bag3 per uso terapeutico
PCT/IB2014/059416 WO2014147503A2 (en) 2013-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use

Publications (1)

Publication Number Publication Date
CN104902927A true CN104902927A (zh) 2015-09-09

Family

ID=48227407

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480003897.1A Pending CN104902927A (zh) 2013-03-18 2014-03-04 用于治疗用途的抗-bag3抗体

Country Status (9)

Country Link
US (2) US20150329622A1 (https=)
EP (1) EP2976104B1 (https=)
JP (1) JP6475225B2 (https=)
KR (1) KR20150129649A (https=)
CN (1) CN104902927A (https=)
CA (1) CA2895472C (https=)
ES (2) ES2721935T3 (https=)
IT (1) ITMI20130403A1 (https=)
WO (1) WO2014147503A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
CN108350065A (zh) * 2015-11-05 2018-07-31 比奥尤尼沃萨有限责任公司 人源化的抗bag3抗体
CN109923127A (zh) * 2016-11-07 2019-06-21 比奥尤尼沃萨有限责任公司 用于治疗性用途的抗bag3抗体与免疫检查点抑制剂的组合
CN114533877A (zh) * 2022-03-09 2022-05-27 上海交通大学医学院附属第九人民医院 Bag3抑制剂在制备治疗瘢痕产品中的用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131351A1 (it) 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
WO2026074330A1 (en) 2024-10-01 2026-04-09 Fibrosys S.R.L. Antibodies and diagnostic methods for detecting bag3 protein in clinical samples

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055908A2 (en) * 2001-12-28 2003-07-10 Arturo Leone Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774355B2 (en) * 1998-09-09 2004-06-24 Burnham Institute, The Novel bag proteins and nucleic acid molecules encoding them
WO2009014759A2 (en) * 2007-07-25 2009-01-29 The Trustess Of Columbia University In The City Of New York Methods of inhibiting vzv replication and related compositions
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
EP2676966A1 (en) * 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 as biochemical serum and tissue marker

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055908A2 (en) * 2001-12-28 2003-07-10 Arturo Leone Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALESSANDRA ROSATI ET AL.: "Expression of the Antiapoptotic Protein BAG3 Is a Feature of Pancreatic Adenocarcinoma and Its Overexpression Is Associated With Poorer Surival", 《THE AMERICAN JOURNAL OF PATBOLOGY》 *
MICHELINA FESTA ET AL.: "BAG3 Protein Is Overexpressed in Human Glioblastoma and Is a Potential Target for Therapy", 《THE AMERICAN JOURNAL OF PATBOLOGY》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108350065A (zh) * 2015-11-05 2018-07-31 比奥尤尼沃萨有限责任公司 人源化的抗bag3抗体
CN108350065B (zh) * 2015-11-05 2022-04-05 比奥尤尼沃萨有限责任公司 人源化的抗bag3抗体
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
CN109923127A (zh) * 2016-11-07 2019-06-21 比奥尤尼沃萨有限责任公司 用于治疗性用途的抗bag3抗体与免疫检查点抑制剂的组合
CN114533877A (zh) * 2022-03-09 2022-05-27 上海交通大学医学院附属第九人民医院 Bag3抑制剂在制备治疗瘢痕产品中的用途

Also Published As

Publication number Publication date
WO2014147503A3 (en) 2014-12-04
US20150329622A1 (en) 2015-11-19
ITMI20130403A1 (it) 2014-09-19
JP2016516078A (ja) 2016-06-02
ES2650942T3 (es) 2018-01-23
WO2014147503A2 (en) 2014-09-25
JP6475225B2 (ja) 2019-02-27
ES2721935T3 (es) 2019-08-06
US20190010221A1 (en) 2019-01-10
CA2895472A1 (en) 2014-09-25
KR20150129649A (ko) 2015-11-20
EP2976104A2 (en) 2016-01-27
EP2976104B1 (en) 2019-01-30
US11117957B2 (en) 2021-09-14
CA2895472C (en) 2022-07-05

Similar Documents

Publication Publication Date Title
US11117957B2 (en) Anti-BAG3 antibodies for therapeutic use
US20220162331A1 (en) Anti-cd73 monoclonal antibody and application thereof
RU2598711C2 (ru) Антитело к противоопухолевому антигену и способы применения
KR20200016899A (ko) 활성화가능 항-pdl1 항체, 및 이의 이용 방법
CN111491661B (zh) M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途
WO2019098763A9 (ko) 알파-시누클레인에 대한 항체 및 그 용도
ES2724364T3 (es) Procedimiento de tratamiento de fibrosis pulmonar idiopática
US20170267768A1 (en) Protein A Binding Polypeptides, Anti-EphA2 Antibodies and Methods of Use Thereof
JP7517702B2 (ja) Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
US10035848B2 (en) Antibody targeting cell surface deposited complement protein C3d and use thereof
US11851496B2 (en) Antibodies against the human fshr extracellular domain
CA3136975C (en) Anti-tie2 antibody and use thereof
KR20250008730A (ko) Ror1-표적화 결합 분자 및 이의 용도
CA3167921A1 (en) Clathrin-chimeric antibody receptor constructs for immune cell activation therapy in vivo
BR112018072140B1 (pt) Anticorpos anti-basigin humanizados, sequência de ácidos nucleicos, composição e uso dos mesmos
WO2017160938A1 (en) METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH α8β1 INTEGRIN
RU2018136094A (ru) Антитело против подокаликсина и tra-родственного белка, способы его получения и применения в качестве противоопухолевого терапевтического средства

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220921

Address after: Baronisi, Salerno, Italy

Applicant after: Phibrosis LLC

Address before: Italy Salerno Faith Siano

Applicant before: BIOUNIVERSA S.R.L.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150909